Related Experiment Video
Updated: May 1, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases
Megha Haridas Upadya1, Jude Juventus Aweya1, Yee-Joo Tan1
1Megha Haridas Upadya, Jude Juventus Aweya, Yee-Joo Tan, Department of Microbiology, Yong Loo Lin School of Medicine, National University Health System (NUHS), National University of Singapore, Singapore 117597, Singapore.
Abstract:
The current therapeutic regimen to combat chronic hepatitis C is not optimal due to substantial side effects and the failure of a significant proportion of patients to achieve a sustained virological response. Recently developed direct-acting antivirals targeting hepatitis C virus (HCV) enzymes reportedly increase the virologic response to therapy but may lead to a selection of drug-resistant variants. Besides direct-acting antivirals, another promising class of HCV drugs in development include host targeting agents that are responsible for interfering with the host factors crucial for the viral life cycle. A family of host proteins known as DEAD-box RNA helicases, characterized by nine conserved motifs, is known to play an important role in RNA metabolism. Several members of this family such as DDX3, DDX5 and DDX6 have been shown to play a role in HCV replication and this review will summarize our current knowledge on their interaction with HCV. As chronic hepatitis C is one of the leading causes of hepatocellular carcinoma, the involvement of DEAD-box RNA helicases in the development of HCC will also be highlighted. Continuing research on the interaction of host DEAD-box proteins with HCV and the contribution to viral replication and pathogenesis could be the panacea for the development of novel therapeutics against HCV.
Insights
New hepatitis C virus (HCV) therapies target host DEAD-box RNA helicases. Understanding these interactions may lead to better treatments for chronic hepatitis C and reduce liver cancer risk.
Area of Science:
- Virology
- Molecular Biology
- Hepatology
Background:
- Current chronic hepatitis C treatments have limitations, including side effects and low sustained virologic response rates.
- Direct-acting antivirals show promise but can lead to drug resistance.
- Host targeting agents offer a novel therapeutic strategy by interfering with host factors essential for viral replication.
Purpose of the Study:
- To review the role of DEAD-box RNA helicases in hepatitis C virus (HCV) replication.
- To summarize current knowledge on the interaction between specific DEAD-box proteins (DDX3, DDX5, DDX6) and HCV.
- To highlight the involvement of these helicases in hepatocellular carcinoma (HCC) development.
Main Methods:
- Literature review summarizing existing research on DEAD-box RNA helicases and HCV.
- Analysis of the known functions of DEAD-box proteins in RNA metabolism and viral life cycles.
- Examination of studies linking these host factors to HCV replication and pathogenesis.
Main Results:
- DEAD-box RNA helicases are crucial host factors involved in RNA metabolism.
- Specific DEAD-box proteins (DDX3, DDX5, DDX6) have been identified as interacting with HCV.
- These interactions are implicated in viral replication and may contribute to the development of hepatocellular carcinoma.
Conclusions:
- DEAD-box RNA helicases represent promising targets for novel anti-HCV therapeutics.
- Further research into the interplay between host DEAD-box proteins and HCV is essential for developing effective treatments.
- Understanding these interactions could pave the way for new strategies against chronic hepatitis C and associated liver cancer.
Related Concept Videos
Viruses with RNA Genomes
Hepatitis
Size and Structure of Viral Genomes
DNA Helicases
Retrovirus Life Cycles
Leaky Scanning

